Benign Diseases Flashcards

1
Q

Benign tutors are harmless except:

A
  1. Where they cause problems due to pressure (i.e., brain, mediastinum)
  2. Where they cause incidental complication (i.e., hemorrhage)
  3. Where they stimulate hormone production (i.e., pituitary)
  4. Where subsequent malignant change occurs (i.e. intestinal polyps)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Rules to use RT on benign disease?

A
  1. The potential risk must be recognized
  2. Safer acceptable methods should be used when available
  3. The RT technique should be optimal to reduce late skin and other organ damage as much as possible
  4. Irradiation of paediatrics rare
  5. Avoid organs at risk: thyroid, gonads, eyes, bone marrow, breast
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Clinical presentation of Dupuytren’s Contracture

A

-Affects connective tissue of hands and feet
Early phase: firm nodule on palm of hand
-turns into a contracture in the Active phase
-Advanced stage: fibrous cords pull the fascia, which pulls the fingers towards the palms

Bilateral (50% of cases)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Risk factors of Dupuytren’s Contracture

A

Age: after the age of 50
Sex: men are more likely
Ancestry: Northern European
Family history: runs in family
Alcohol and smoking are associated with Duputren’s
People with diabetes are reported to have an increased risk of Dupuytren’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Dupuytren’s Contracture-Treatment

A

Surgery: needle fasciotomy; surgery with skin graft
Radiation Treatment: (for early stage nodules)
-Orthovoltage: 120 KVP, split course 15 Gy/ 5 fr, 12 weeks then 15 Gy/5 Fr, lead shielding and direct apposition
-Electrons: 6-12 MEV, custom shielding and bolus, 21 Gy/ 3 fr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Grave’s disease

A

Hyperthyroidism- immune disease that results in the production of thyroid hormones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Risk factors of Grave’s disease

A
Family history-genetic component
Gender-women
Age-younger than 40
Other autoimmune disorders-such as type 1 diabetes or rheumatoid arthritis 
Pregnancy and smoking
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Graves ophthalmopathy

A

Overproduction of cytokines that affect muscles and other tissues around the eyes.

Symptoms:

  • exophthalmos/proptosis
  • Gritty sensation in eyes
  • Pressure/pain in eyes
  • Puffy/retracted eyelids
  • Reddened or inflamed eyes
  • light sensitivity, double vision, vision loss
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Grave’s ophthalmopathy treatment

A
  • IMRT/3D-CRT/LOF
  • IMRT gives better distribution
  • Small unilateral fields (half beam block, 4cm x 4cm)
  • 5 degree gantry angle to push field posteriorly and avoid the lens
  • 6 MV photons
  • 20 Gy/10 fr
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Arteriovenous Malformations (AVMs)

A
  • congenial defects of circulatory system
  • masses of abnormal blood vessels
  • can grow over time and exert pressure
  • spine and brain are of most concern
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

AVM risks

A
  • age: 20-40 years
  • possible genetic component but not inherited
  • greatest risk from an AVM is a hemorrhage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

AVM symptoms

A
  • depends on where the AVM is located
  • bleeding
  • progressive loss of neurological function
  • headaches, nausea, and vomiting
  • seizures
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

AVM treatment

A

Surgery: preferred tx because of risk of hemorrhage with RT. Non-surgical candidates get SRS
RT: Gamma knife or linac to thicken vascular wall. Small AVMs are more effectively treated due to larger doses possible

SRS:

  • lesion <3cm 21-22 Gy to the margin
  • lesion >3cm 16-18 Gy to the margin

takes 1-3 years to decrease bleeding risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Keloids

A

Overgrown scar-collagenous tissue is overproduced and grows beyond the wound.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Keloids etiology

A

Derma injuries (burns, piercings, chicken pox, biopsy site, lacerations, acne)

Can become elevated, painful, itchy, fibrotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Keloids epidemiology

A

Age: 10-30
Genetic risk factors
Darkly pigmented skin
Black, Hispanic, or Asian heritage

Likely to occur on earlobes, chest, shoulders, upper arms, upper back, back of neck, cheeks or knees

17
Q

Keloids treatment

A
  1. Surgical Re-excision
  2. Injections (steroids, bleomycin, botox, interferon)
  3. Laser therapy
  4. Cryotherapy
  5. PORT
18
Q

RT for Keloids

A
  • Only used in adults
  • irradiation dec. rate of healing of skin tissue
  • must occur soon after surgery (24-72 hours preferably)
  • Single field, KV, MEV, shielding, 10-15 Gy/2-3 fr….37.5 Gy/ 25 fr
19
Q

Side effects of RT for Keloids

A

Acute: epilation, erythema
Chronic: pigmentation, atrophy, telangiectasia

20
Q

Craniopharyngioma

A

-usually made up of a solid mass and fluid filled cyst, as well as calcium deposits (visible on x-rays)

21
Q

Who tends to have craniopharyngiomas?

A

-Etiology unknown
-Rare-approx 1% of adult brain tumours and 6% childhood brain tumours
Bi-modal: 5-14 years and 50-60s

22
Q

Presenting symptoms of craniopharyngiomas

A

Result from compression of the pituitary gland, optic nerve or hypothalamus

  • impaired hormone function: excessive urination, delayed puberty and growth failure, decreased sexual drive and impotence or amenorrhea
  • increased brain pressure: headache, fatigue
  • loss of vision
23
Q

Treatment for craniopharyngiomas

A

Surgery: craniotomy, transsphenoidal excision
RT: post surgical, IMRT, SRS, proton, interstitial
Targeted therapy: Papillary craniopharyngioma: BRAF gene mutation

24
Q

Craniopharyngioma RT prescription

A

EBRT: 5040-5400 cGy, 180 cGy/fr

SRS with gamma knife: 9-20 Gy/1 fr (to margin), 20-50 Gy/1 fr (max dose)

25
Q

10 year survival of craniopharngiomas?

A

80-90%

26
Q

Acoustic neuroma/vestibular schwannoma

A
  • non-cancerous tumor that develops on the main vestibular nerve
  • caused by genetic abnormality chromosome 22
  • vestibulocochlear nerve (8th CN)
  • affects balance and hearing
  • 50-55 years of age

Symptoms: hearing loss, headache, tinnitus, vertigo and imbalance, facial numbness

27
Q

Acoustic neuroma treatment options

A

Can cause hydrocephalus leading to intracranial pressure

Options:

  • watchful waiting
  • surgery
  • RT
28
Q

RT for acoustic neuroma

A

FSRT-Fractionated stereotactic RT
SRS with Gamma knife
-control tumor growth and minimize injury to trigeminal and facial nerves
-tumor <2-3.5 cm, older in age and not a surgical candidate
-Dose 11-14 Gy/ 1 fr

29
Q

Pterygium/Surfer’s eye

A

-Growth on the conjunctival epithelium onto the cornea

30
Q

Pterygium risk factors

A
  • living in the tropics, close to the equator
  • working in sandy outdoor space
  • not wearing sunglasses
  • not wearing a hat (exposure to UV)
  • chronic eye irritation
  • local drying of the conjunctiva and tear film abnormalities
  • Ages: 20-49, rarely occurs under age 15
31
Q

Pterygium symptoms

A
  • burning, itching, tearing, foreign body sensation
  • astigmatism may be induced
  • in severe cases symblepharon formation (adhesions) may limit ocular motility and result in diplopia (double vision)
32
Q

Pterygium treatment

A
  • Surgical excision (20-80% recurrence)
  • Recurrence can be treated with steroids, topical mitomycin c (antineoplastic), Bevacizumab (antivascular endothelial growth factor)
  • RT added to surgery helps prevent recurrence
  • RT not a commonly used modality
33
Q

RT treatment for Pterygium

A

-Strontium 90 applicator used that provides minimal dose to lens
-applicator applied directly to surgical bed and tx is within 48 hours of surgery
-800-900 cGy once weekly for 3 treatments
or
-1700 cGy in 1 fraction

34
Q

Pterygium prognosis

A

> 90% recurrence within first month after excision and recurrent is more aggressive than primary disease

35
Q

Ectopic bone formation/heterotopic ossification

A

-Excess bone broth following surgery (notably hip replacement surgery)

36
Q

Ectopic bone formation risk factors

A
  • Male gender
  • Age >65
  • Post traumatic arthritis
  • Hypertrophic osteoarthritis
  • Active ankylosing spondylitis
37
Q

Ectopic bone formation treatment

A
  • mainstay NSAIDS

- RT

38
Q

RT for ectopic bone formation

A
  • should follow surgery within a week of the surgical procedure (preferably within 48 hours)
  • Cobalt-60 or low MV photons
  • POP
  • 700-800 cGY in 1 fraction or 2000 cGy/ 10 fractions
  • 95% effectiveness